{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:54:35Z","timestamp":1790420075048,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.parkreldis.2018.12.022","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T08:22:18Z","timestamp":1545207738000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Current treatment of tardive dyskinesia"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8735-0796","authenticated-orcid":false,"given":"Adam","family":"Margolius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2018.12.022_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jns.2018.02.005","article-title":"Tardive syndromes","volume":"389","author":"Savitt","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2018.02.008","article-title":"The nosology of tardive syndromes \u2606","volume":"389","author":"Frei","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.nrl.0000038585.58012.97","article-title":"Classification and treatment of tardive syndromes","volume":"9","author":"Fernandez","year":"2003","journal-title":"Neurol."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00002826-199506000-00001","article-title":"Tardive syndromes and other drug-induced movement disorders","volume":"18","author":"Jankovic","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib5","series-title":"An Update on Tardive Dyskinesia\u202f: from Phenomenology to Treatment, Tremor and Other Hyperkinetic Movements","first-page":"1","author":"Waln","year":"2013"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib6","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","author":"Carbon","year":"2017","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib7","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","author":"Woods","year":"2010","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00406-006-0705-z","article-title":"The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study","volume":"257","author":"De Leon","year":"2007","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia \u2606","volume":"389","author":"Solmi","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib10","series-title":"Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium","year":"2000"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib11","first-page":"1","article-title":"Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic","volume":"4","author":"Zutshi","year":"2014","journal-title":"Tremor Other Hyperkinetic Mov."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-0447.1996.tb09835.x","article-title":"Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia","volume":"94","author":"Browne","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10401238909149978","article-title":"Changes in tardive dyskinesia after fluphenazine decanoate discontinuation","volume":"1","author":"Peselow","year":"1989","journal-title":"Ann. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib14","doi-asserted-by":"crossref","DOI":"10.3310\/hta21430","article-title":"Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia","volume":"21","author":"Bergman","year":"2017","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-198105000-00005","article-title":"Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics","author":"Shenoy","year":"1981","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0140-6736(80)90107-5","article-title":"Covert dyskinesia in ambulatory schizophrenia","volume":"2","author":"Carpenter","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archpsyc.1983.01790220020003","article-title":"Anticholinergic challenge and neuroleptic withdrawal: changes in dyskinesia and symptom measures","volume":"41","author":"Gardos","year":"1984","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-Year follow-up","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"issue":"8, Sect 2","key":"10.1016\/j.parkreldis.2018.12.022_bib19","first-page":"4","article-title":"Molindone and haloperidol in tardive dyskinesia","volume":"46","author":"Glazer","year":"1985","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/0022-510X(75)90165-3","article-title":"Tardive dyskinesia treated with pimozide","author":"Claveria","year":"1975","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib21","article-title":"Treatment of tardive dyskinesia: II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate","author":"Kazamatsuri","year":"1972","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","author":"Jankovic","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2013.12.003","article-title":"The vesicular monoamine transporter 2: an underexplored pharmacological target","author":"Bernstein","year":"2014","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1345\/aph.1P312","article-title":"Tetrabenazine for the treatment of tardive dyskinesia","volume":"45","author":"Leung","year":"2011","journal-title":"Ann. Pharmacother."},{"issue":"7 Supplement","key":"10.1016\/j.parkreldis.2018.12.022_bib27","article-title":"The pharmacokinetics and safety of deuterated-tetrabenazine (P07.210)","volume":"80","author":"Stamler","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib28","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005817","article-title":"Evaluating depression and suicidality in tetrabenazine users with Huntington disease","author":"Schultz","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib29","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S1092852918001219","article-title":"Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.116.239160","article-title":"Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites","volume":"361","author":"Grigoriadis","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543784.2015.1029573","article-title":"Valbenazine granted breakthrough drug status for treating tardive dyskinesia","volume":"24","author":"M\u00fcller","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib35","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11777","article-title":"The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study","author":"Factor","year":"2017","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib36","article-title":"Neurobiological substrates of tardive dyskinesia: the GABA hypothesis","author":"Fibiger","year":"1984","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/106002808301700705","article-title":"Diazepam in tardive dyskinesia","volume":"17","author":"Weber","year":"1983","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib38","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","article-title":"Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy","volume":"147","author":"Thaker","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00431840","article-title":"Effect of baclofen on tardive dyskinesia","volume":"56","author":"Gerlach","year":"1978","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00002826-198212000-00004","article-title":"Baclofen in tardive dyskinesia patients maintained on neuroleptics","volume":"5","author":"Stewart","year":"1982","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF00432517","article-title":"The treatment of tardive dyskinesia with baclofen","volume":"87","author":"Glazer","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.parkreldis.2018.12.022_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2007-971169","article-title":"Tardive dyskinesia","volume":"27","author":"Soares-Weiser","year":"2007","journal-title":"Semin. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.12.022_bib44","first-page":"167","article-title":"A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia","volume":"57","author":"Lohr","year":"1996","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib45","article-title":"Vitamin E treatment of tardive dyskinesia","author":"Adler","year":"1993","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib46","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","article-title":"V.A.C.S. #394 S. Group, vitamin E treatment for tardive dyskinesia","volume":"56","author":"Adler","year":"1999","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib48","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.v65n0516","article-title":"A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia","volume":"65","author":"Emsley","year":"2004","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib49","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","article-title":"A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia","volume":"71","author":"Chan","year":"2010","journal-title":"J. Clin. Psychiatr."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.12.022_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3928\/0279-3695-19930901-07","article-title":"The effect of clozapine on preexisting tardive dyskinesia","volume":"31","author":"Littrell","year":"1993","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib51","first-page":"319","article-title":"Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients","author":"Spivak","year":"1997","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00571412","article-title":"Clozapine in tardive dyskinesia","volume":"56","author":"Simpson","year":"1978","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl B","key":"10.1016\/j.parkreldis.2018.12.022_bib53","first-page":"102","article-title":"Clozapine in tardive dyskinesia: observations from human and animal model studies","volume":"55","author":"Tamminga","year":"1994","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib54","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis - incidence and risk factors in the United States","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib55","doi-asserted-by":"crossref","DOI":"10.1007\/BF00606409","article-title":"Agranulocytosis during treatment with clozapine","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","author":"Albin","year":"1989","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib57","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-199704000-00004","article-title":"A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia","author":"Angus","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/1531-8257(200003)15:2<352::AID-MDS1030>3.0.CO;2-X","article-title":"Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia","author":"Rapaport","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20904","article-title":"Botulinum toxin as a treatment for tardive dyskinesia","author":"van Harten","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib61","doi-asserted-by":"crossref","DOI":"10.2147\/NDT.S62490","article-title":"The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study","author":"Yasui-Furukori","year":"2014","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/mds.10705","article-title":"Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia","author":"Schrader","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0404.2008.01115.x","article-title":"A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation","volume":"119","author":"Kefalopoulou","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib64","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.64.2.170","article-title":"Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia","author":"Damier","year":"2007","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.12.022_bib65","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0000000000002370","article-title":"Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia","volume":"86","author":"Pouclet-Courtemanche","year":"2016","journal-title":"Neurology"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380201830556X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380201830556X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T19:23:27Z","timestamp":1662665007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380201830556X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":65,"alternative-id":["S135380201830556X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.12.022","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current treatment of tardive dyskinesia","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}